As the research for anti-obesity drugs is ongoing, it is possible that better knowledge about the types and locations of causative congenital deleterious PNLIP gene mutations might aid in designing and targeting critical domains of PNLIP. Here, PNLIP is linked to obesity due to melanocortin 4 receptor deficiency.